(Corrects spelling of pneumococcal in headline)
(Reuters) - Pfizer Inc said on Monday it has started immunizing the first patients in a new study looking at administering the company's 20-valent pneumococcal conjugate vaccine candidate following a booster dose of the Pfizer-BioNTech COVID-19 shot.
The study will include 600 adults over 65 years who will be recruited from the late-stage study of the Pfizer-BioNTech COVID-19 vaccine, and will have received their second dose of the vaccine at least six months prior to entering the co-administration study, the company said.
(This story has been refiled to correct spelling of pneumococcal in headline)
(Reporting by Vishwadha Chander in Bengaluru; Editing by Sriraj Kalluvila)